The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss. Objective: Obesity affects more than 40 ...

Doctors should try to understand their patients’ eating behaviours before prescribing weight loss drugs, researchers said.

The popular drugs worked well to help children and adolescents lose weight and lower their blood sugar levels, a new review ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received glucagon-like peptide-1 receptor ...

Please provide your email address to receive an email when new articles are posted on . Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or ...

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) - prescription ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

This cohort study found that glucagon-like peptide-1 receptor agonist (GLP-1RA) prescriptions were associated with a lower risk of uveitis compared with controls. These findings suggest potential anti ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay News) ...